CA3061270C - Bladder instillation composition containing chondroitin sulfate (20 mg/ml), hyaluronic acid (16 mg/ml), and a phosphate buffer (ph 6.1 to 7.9) with increased storage stability for treating cystitis - Google Patents

Bladder instillation composition containing chondroitin sulfate (20 mg/ml), hyaluronic acid (16 mg/ml), and a phosphate buffer (ph 6.1 to 7.9) with increased storage stability for treating cystitis Download PDF

Info

Publication number
CA3061270C
CA3061270C CA3061270A CA3061270A CA3061270C CA 3061270 C CA3061270 C CA 3061270C CA 3061270 A CA3061270 A CA 3061270A CA 3061270 A CA3061270 A CA 3061270A CA 3061270 C CA3061270 C CA 3061270C
Authority
CA
Canada
Prior art keywords
composition
component
average molecular
molecular weight
hyaluronic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA3061270A
Other languages
English (en)
French (fr)
Other versions
CA3061270A1 (en
Inventor
Andreas Meier
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Farco Pharma GmbH
Original Assignee
Farco Pharma GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Farco Pharma GmbH filed Critical Farco Pharma GmbH
Publication of CA3061270A1 publication Critical patent/CA3061270A1/en
Application granted granted Critical
Publication of CA3061270C publication Critical patent/CA3061270C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M3/00—Medical syringes, e.g. enemata; Irrigators
    • A61M3/02—Enemata; Irrigators
    • A61M3/0266—Stands, holders or storage means for irrigation devices
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Inorganic Chemistry (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA3061270A 2017-05-12 2018-05-02 Bladder instillation composition containing chondroitin sulfate (20 mg/ml), hyaluronic acid (16 mg/ml), and a phosphate buffer (ph 6.1 to 7.9) with increased storage stability for treating cystitis Active CA3061270C (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP17000820 2017-05-12
EP17000820.5 2017-05-12
EP17173817.2 2017-05-31
EP17173817.2A EP3400950B1 (de) 2017-05-12 2017-05-31 Blaseninstillationszusammensetzung enthaltend chondoitinsulfat (20 mg/ml), hyaluronsäure (16 mg/ml) und phosphatpuffer (ph 6,1 bis 7,9) mit erhöhter lagerstabiliät zur behandlung von cystitis
PCT/EP2018/061147 WO2018206357A1 (de) 2017-05-12 2018-05-02 Blaseninstillationszusammensetzung enthaltend chondoitinsulfat (20 mg/ml), hyaluronsäure (16 mg/ml) und phosphatpuffer (ph 6,1 bis 7,9) mit erhöhter lagerstabiliät zur behandlung von cystitis

Publications (2)

Publication Number Publication Date
CA3061270A1 CA3061270A1 (en) 2018-11-15
CA3061270C true CA3061270C (en) 2022-11-22

Family

ID=58709188

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3061270A Active CA3061270C (en) 2017-05-12 2018-05-02 Bladder instillation composition containing chondroitin sulfate (20 mg/ml), hyaluronic acid (16 mg/ml), and a phosphate buffer (ph 6.1 to 7.9) with increased storage stability for treating cystitis

Country Status (7)

Country Link
US (1) US11141424B2 (de)
EP (1) EP3400950B1 (de)
KR (1) KR102312643B1 (de)
CA (1) CA3061270C (de)
ES (1) ES2769059T3 (de)
RU (1) RU2745869C1 (de)
WO (1) WO2018206357A1 (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021009525A1 (en) * 2019-07-18 2021-01-21 Lovasz Sandor Medicinal and/or pharmaceutical compositions for intravesical instillation, preparation and use thereof
EP4262748A1 (de) * 2020-12-21 2023-10-25 Biointelligent Technology Systems SLU Mukosale reepithelisierungszusammensetzung

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5880108A (en) 1995-02-14 1999-03-09 Bioniche, Inc. Method for treating the internal urinary bladder and associated structures using hyaluronic acid
US6083933A (en) 1999-04-19 2000-07-04 Stellar International Inc. Treatment of cystitis-like symptoms with chondroitin sulfate following administration of a challenge solution
US7820194B2 (en) * 2001-12-21 2010-10-26 Alcon, Inc. Combinations of viscoelastics for use during surgery
US20040161476A1 (en) 2003-02-19 2004-08-19 Hahn Sungtack Samuel Cystitis treatment with high dose chondroitin sulfate
ITMI20061030A1 (it) * 2006-05-26 2007-11-27 Altergon Sa Nuova composizione comprendente glicosamminoglicani a viscosita' controllata e uso di tale composizione nella terapuia della cistite cronica
DE102006060953A1 (de) * 2006-12-12 2008-08-07 Farco-Pharma Gmbh Pharmazeutische Zubereitung für die Behandlung entzündlicher Erkrankungen des Urogenitaltraktes
US20080275015A1 (en) * 2007-05-01 2008-11-06 Potter Jeffrey A Formulation and Method for Treating Interstitial Cystitis and Related Bladder Conditions
ITPD20120098A1 (it) * 2012-03-30 2013-10-01 Fidia Farmaceutici "nuove formulazioni faramaceutiche contenenti condroitin solfato e derivati dell'acido ialuronico"
WO2013153550A2 (en) * 2012-04-08 2013-10-17 Theracoat Ltd Reverse thermal hydrogel preparations for use in the treatment of disorders of the urothelium
ITMI20120896A1 (it) * 2012-05-23 2013-11-24 Bongulielmi Reto Condroitina per uso in medicina
CN105982912A (zh) * 2015-03-02 2016-10-05 黄绣川 一种包含透明质酸钠和硫酸软骨素的药物组合物

Also Published As

Publication number Publication date
CA3061270A1 (en) 2018-11-15
ES2769059T3 (es) 2020-06-24
KR102312643B1 (ko) 2021-10-15
US11141424B2 (en) 2021-10-12
US20210137968A1 (en) 2021-05-13
RU2745869C1 (ru) 2021-04-02
WO2018206357A1 (de) 2018-11-15
EP3400950B1 (de) 2019-11-13
EP3400950A1 (de) 2018-11-14
KR20200004833A (ko) 2020-01-14

Similar Documents

Publication Publication Date Title
RU2403012C2 (ru) Мукоадгезивные ксилоглюкансодержащие препараты, полезные в медицинских устройствах и в фармацевтических препаратах
WO2008071245A1 (de) Pharmazeutische zubereitung für die behandlung entzündlicher erkrankungen des urogenitaltraktes
CZ257497A3 (cs) Použití kyseliny hyaluronové pro léčené intersticiální cistitidy
RU2308951C2 (ru) Комплексный способ профилактики вагинальных дисбактериозов (варианты)
CA3061270C (en) Bladder instillation composition containing chondroitin sulfate (20 mg/ml), hyaluronic acid (16 mg/ml), and a phosphate buffer (ph 6.1 to 7.9) with increased storage stability for treating cystitis
Tomas et al. Sodium bicarbonate gels: a new promising strategy for the treatment of vulvovaginal candidosis
US11766421B2 (en) Ophthalmic pharmaceutical compositions and methods for treating ocular surface disease
EP3153156A1 (de) Zusammensetzung auf basis einer stabilisierten lösung von wirkstoffen
US11351113B2 (en) Bladder instillation composition with increased storage stability and containing chondroitin sulfate (4.5 mg/ml), hyaluronic acid (16 mg/ml) and phosphate buffer (PH 6.1 to 7.9), for the treatment of cystitis
RU2309744C1 (ru) Способ лечения послеродового эндометрита
US9827274B2 (en) Enemas
BR112013029661B1 (pt) Uso de uma macromolécula compreendendo um dendrímero para a preparação de um medicamento para o tratamento ou profilaxia de vaginose bacteriana
CN100536855C (zh) 一种聚维酮碘药物制剂及其制备方法
DE202017103288U1 (de) Zusammensetzung für die Behandlung entzündlicher Erkrankungen des Urogenitaltraktes in Form einer hochdosierten Wirkstoffkombination
CN107174577A (zh) 一种含有egcg的凝胶剂及其制备方法
Regu et al. Ocular Delivery of Metformin for Sustained Release and in Vivo Efficacy
EP3415163B1 (de) Zusammensetzung mit lokalanästhetischer wirkung und deren verwendung
DE202017103289U1 (de) Zusammensetzung für die Behandlung entzündlicher Erkrankungen des Urogenitaltraktes in Form einer Wirkstoffkombination
EP3496731B1 (de) Zusammensetzung zur behandlung von erkrankungen der harnwege
DE202017104675U1 (de) Zusammensetzung mit lokalanästhetischer Wirkung und deren Verwendung
Samy et al. Design, in vitro and in vivo evaluation of Fluconazole Bioadhesive Vaginal tablets
CN116251118A (zh) 一种人工唾液、人工唾液爆珠及其制备和在口干症中的应用
Aron, R. & Gordon Pulmonary nocardiosis-case report and evaluation of current therapy
UA69729A (en) Method for correcting peroxidation in patients with multiple peptic ulcers of stomach and duodenum upon surgical treatment

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20200204

EEER Examination request

Effective date: 20200204

EEER Examination request

Effective date: 20200204

EEER Examination request

Effective date: 20200204

EEER Examination request

Effective date: 20200204